Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

MORPHOSYS : to Present at Upcoming Investor Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/02/2011 | 04:05pm CEST

MorphoSys AG / MorphoSys to Present at Upcoming Investor Conference Processed and transmitted by Thomson Reuters. The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that Chief Executive Officer Dr Simon Moroney will present at the upcoming Société Générale Healthcare and Biotechnology Conference in Paris.

 

Société Générale Healthcare and Biotechnology Conference
Date: February 9, 2011
Venue: Paris, France
Presenter: Dr. Simon Moroney, CEO of MorphoSys AG

 

A PDF version of the company presentation is provided at www.morphosys.com:
http://www.morphosys.com/

 

 

 

 

+++MorphoSys will publish its Full Year 2010 Results on February 24, 2011+++

 

 

About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company's HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world's leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation. Its most advanced program MOR103, a first-in-class, fully human antibody against GM-CSF, is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol "MOR". For further information, visit http://www.morphosys.com/:
http://www.morphosys.com/

 

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay® and RapMAT® are registered trademarks of MorphoSys. arYlaTM is a trademark of MorphoSys.

 

 

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

 

 

 

 

For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

 

Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

 

Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

 

investors@morphosys.com:
mailto:investors@morphosys.com

 

Press Release:
http://hugin.info/130295/R/1484742/419929.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE


HUG#1484742


share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MORPHOSYS AG
03/23 MORPHOSYS AG : MorphoSys's CSO Marlies Sproll Takes Temporary Leave, Markus Enze..
03/23 MORPHOSYS : CSO Marlies Sproll Takes Temporary Leave Markus Enzelberger to Serve..
03/23 DGAP-NEWS : MorphoSys' Forschungsvorstand Marlies Sproll nimmt vorübergehend Aus..
03/23 DGAP-NEWS : MorphoSys's CSO Marlies Sproll Takes Temporary Leave Markus Enzelber..
03/09 MORPHOSYS : Patent Issued for Combinations and Uses (USPTO 9579378)
03/09 MORPHOSYS AG : Presents Strong Results for Fiscal Year 2016
03/09 MORPHOSYS : Presents Strong Results for Fiscal Year 2016
03/09 DGAP-NEWS : MorphoSys AG berichtet über ein starkes Geschäftsjahr 2016
03/09 DGAP-NEWS : MorphoSys AG Presents Strong Results for Fiscal Year 2016
03/06 MORPHOSYS : Announces That Its Licensee Janssen Has Reported New Data From Two P..
More news
Sector news : Biotechnology & Medical Research - NEC
06:27pDJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
06:12pDJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
03/09 MorphoSys' (MPSYF) CEO Simon Moroney on Q4 2016 Results - Earnings Call Trans..
03/09 MorphoSys AG reports Q4 results
03/09 MorphoSys AG 2016 Q4 - Results - Earnings Call Slides
01/12 Novartis to launch mid-stage study of bimagrumab in obese type 2 diabetics
01/10 RHEUMATOID ARTHRITIS : The Big 3 And The Future
Advertisement
Financials (€)
Sales 2017 52,3 M
EBIT 2017 -43,4 M
Net income 2017 -46,4 M
Finance 2017 257 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 24,4x
EV / Sales 2018 29,2x
Capitalization 1 534 M
More Financials
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Full-screen chart
Technical analysis trends MORPHOSYS AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 66,5 €
Spread / Average Target 26%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Simon E. Moroney Chief Executive Officer
Gerald Heinz Möller Chairman-Supervisory Board
Jens Holstein Chief Financial Officer
Marlies Sproll Chief Scientific Officer
Steffen Pohlenz Head-Information Technology
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MORPHOSYS AG11.45%1 666
INCYTE CORPORATION39.51%28 512
QUINTILES IMS HOLDINGS..3.48%18 567
LONZA GROUP AG3.40%10 684
CELLTRION, INC.--.--%10 016
SEATTLE GENETICS, INC.22.02%9 175
More Results